Research firm Frost & Sullivan has recognized Volpara Solutions with its 2014 North American Award for Technology Innovation Leadership. The award recognizes companies that have invested significant resources toward developing innovative solutions with relevance to the industry and that positively impact brand perception.

The volumetric breast imaging solutions provider offers products designed for early detection of breast cancer, including the patient-specific solutions VolparaDose and VolparaDensity and the clinic-wide monitoring tools VolparaAnalytics and VolparaResearch. Over the last few years, the company has expanded its global presence into the United States, Europe, Asia, and Australia.

“Frost & Sullivan lauds Volpara Solutions for continuous leadership in technology innovation, thoughtfulness in identifying the unmet need for dose tracking in breast imaging, and a clear vision for what analytics can achieve in the early detection and treatment of breast cancer,” said Siddharth Saha, research director of the firm’s advanced medical technologies group.

“Furthermore, all of the applications are built to serve across both full-field digital mammography and digital tomosynthesis systems, and with multi-vendor compatibility and reproducible data. This is of high relevance in the industry, as tomosynthesis is quickly gaining currency, with 30% of the members of the Society of Breast Imaging in the US already using it,” he added.

VolparaDensity generates an objective measure of breast density and assigns a BI-RADS breast density category, while VolparaDose is the industry’s only dose measurement tool designed specifically for breast imaging. VolparaAnalytics generates metrics to assess the performance of technologists, readers, and mammography and tomosynthesis machines. VolparaResearch assists researchers in analyzing large datasets of breast measurement information.

“We are very proud to be recognized for the innovative solutions we have brought to the breast imaging market and for our vision and commitment to address unmet needs in the detection, prevention, and treatment of breast cancer,” said Ralph Highnam, PhD, Volpara Solutions’ CEO and chief scientist. “By allowing researchers across the globe to compare data to detect geographical, racial, and age-related trends, we hope to take breast cancer research to the next level, which could lead to the development of predictive analytical models that will revolutionize early detection of breast cancer and save lives.”

For more information, visit Volpara Solutions and Frost & Sullivan.